Affiliation: AstraZeneca R and D
- Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trialsWilliam Cook
Medical Affairs, AstraZeneca, Wilmington, DE 19850, USA
Postgrad Med 125:145-54. 2013..This post hoc analysis sought to assess the efficacy, safety, and tolerability of saxagliptin in patients with type 2 diabetes mellitus and cardiovascular (CV) risk factors or disease (CVD)...